Last reviewed · How we verify
Benzbromarone (drug)
Benzbromarone inhibits renal urate reabsorption by blocking the urate transporter URAT1, thereby increasing urinary uric acid excretion and lowering serum uric acid levels.
Benzbromarone inhibits renal urate reabsorption by blocking the urate transporter URAT1, thereby increasing urinary uric acid excretion and lowering serum uric acid levels. Used for Hyperuricemia and gout prophylaxis.
At a glance
| Generic name | Benzbromarone (drug) |
|---|---|
| Sponsor | Tottori University Hospital |
| Drug class | Uricosuric agent |
| Target | URAT1 (urate transporter 1) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology |
| Phase | FDA-approved |
Mechanism of action
Benzbromarone is a uricosuric agent that acts on the apical membrane of proximal tubule cells in the kidney. By inhibiting the urate transporter 1 (URAT1), it prevents the reabsorption of filtered uric acid, promoting its elimination in urine. This mechanism effectively reduces serum uric acid concentrations, making it useful for managing hyperuricemia and gout.
Approved indications
- Hyperuricemia and gout prophylaxis
Common side effects
- Acute gout attack
- Hepatotoxicity
- Renal calculi
- Gastrointestinal disturbances
Key clinical trials
- Exploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release Tablets (PHASE4)
- Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients (PHASE2)
- SGLT2 Inhibition: Uric Acid Excretion Study (PHASE4)
- Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction (PHASE4)
- Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia (PHASE2)
- Compare the Renal Protective Effects of Febuxostat and Benzbromarone (NA)
- Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout (PHASE3)
- Acute Effects of Benzbromaron on the Pulmonary Circulation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Benzbromarone (drug) CI brief — competitive landscape report
- Benzbromarone (drug) updates RSS · CI watch RSS
- Tottori University Hospital portfolio CI